Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine, AYVAKIT/AYVAKYTĀ® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC filing details

Document Details

Form
Filing Date
Nov 24, 2017
Document Date
Nov 21, 2017
Form Description
Amendment to a previously filed 4
Filing Group
3,4,5
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp
Filer
Dorsch Marion